Changes in Utilization and Discard of HCV Antibody-Positive Deceased Donor Kidneys in the Era of Direct-Acting Antiviral Therapy

• Published in: Transplantation Vol. 102; no. 12; p. 2088
• Main Authors: Bowring, Mary G, Kucirka, Lauren M, Massie, Allan B, Ishaque, Tanveen, Bae, Sunjae, Shaffer, Ashton A, Garonzik Wang, Jacqueline, Sulkowski, Mark, Desai, Niraj, Segev, Dorry L, Durand, Christine M
• Format: Journal Article
• Language: English
• Published: United States 01.12.2018
• Subjects: Antiviral Agents - therapeutic use; Biomarkers - blood; Donor Selection; Female; Hepatitis C - blood; Hepatitis C - prevention & control; Hepatitis C - transmission; Hepatitis C - virology; Hepatitis C Antibodies - blood; Humans; Kidney Transplantation - methods; Male; Middle Aged; Patient Acceptance of Health Care; Registries; Risk Assessment; Risk Factors; Time Factors; Tissue Donors - supply & distribution; Treatment Outcome; United States; Waiting Lists; United States
• ISSN: 1534-6080
• DOI: 10.1097/TP.0000000000002323

The availability of direct-acting antiviral (DAA) therapy might have impacted use of hepatitis C virus (HCV)-infected (HCV+) deceased donor kidneys for transplantation. We used 2005 to 2018 Scientific Registry of Transplant Recipients data to identify 18 936 candidates willing to accept HCV+ kidneys and 3348 HCV+ recipients of HCV+ kidneys. We compared willingness to accept, utilization, discard, and posttransplant outcomes associated with HCV+ kidneys between 2 treatment eras (interferon [IFN] era, January 1, 2005 to December 5, 2013 vs DAA era, December 6, 2013 to August 2, 2018). Models were adjusted for candidate, recipient, and donor factors where appropriate. In the DAA era, candidates were 2.2 times more likely to list as willing to accept HCV+ kidneys (adjusted odds ratio, 2.072.232.41; P < 0.001), and HCV+ recipients were 1.95 times more likely to have received an HCV+ kidney (adjusted odds ratio, 1.761.952.16; P < 0.001). Median Kidney Donor Profile Index of HCV+ kidneys decreased from 77 (interquartile range [IQR], 59-90) in 2005 to 53 (IQR, 40-67) in 2017. Kidney Donor Profile Index of HCV- kidneys remained unchanged from 45 (IQR, 21-74) to 47 (IQR, 24-73). After adjustment, HCV+ kidneys were 3.7 times more likely to be discarded than HCV- kidneys in the DAA era (adjusted relative rate, 3.363.674.02; P < 0.001); an increase from the IFN era (adjusted relative rate, 2.783.023.27; P < 0.001). HCV+ kidney use was concentrated within a subset of centers; 22.5% of centers performed 75% of all HCV+ kidney transplants in the DAA era. Mortality risk associated with HCV+ kidneys remained unchanged (aHR, 1.071.191.32 in both eras). Given the elevated risk of death on dialysis facing HCV+ candidates, improving quality of HCV+ kidneys, and DAA availability, broader utilization of HCV+ kidneys is warranted to improve access in this era of organ shortage.